CN113397171A - Composition and application thereof - Google Patents
Composition and application thereof Download PDFInfo
- Publication number
- CN113397171A CN113397171A CN202110585553.8A CN202110585553A CN113397171A CN 113397171 A CN113397171 A CN 113397171A CN 202110585553 A CN202110585553 A CN 202110585553A CN 113397171 A CN113397171 A CN 113397171A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- depression
- group
- adenosylmethionine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 62
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 55
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 27
- 102000004407 Lactalbumin Human genes 0.000 claims abstract description 25
- 108090000942 Lactalbumin Proteins 0.000 claims abstract description 25
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 claims abstract description 25
- 229960001570 ademetionine Drugs 0.000 claims abstract description 25
- 235000021241 α-lactalbumin Nutrition 0.000 claims abstract description 25
- 235000013402 health food Nutrition 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 8
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000000600 sorbitol Substances 0.000 claims description 6
- 235000010356 sorbitol Nutrition 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000013355 food flavoring agent Nutrition 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 201000009916 Postpartum depression Diseases 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 239000004386 Erythritol Substances 0.000 claims description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 229960004106 citric acid Drugs 0.000 claims description 2
- 235000019414 erythritol Nutrition 0.000 claims description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 2
- 229940009714 erythritol Drugs 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 2
- 235000010439 isomalt Nutrition 0.000 claims description 2
- 239000000905 isomalt Substances 0.000 claims description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229940099690 malic acid Drugs 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 2
- 229940013618 stevioside Drugs 0.000 claims description 2
- 235000019202 steviosides Nutrition 0.000 claims description 2
- 239000002417 nutraceutical Substances 0.000 claims 3
- 235000021436 nutraceutical agent Nutrition 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 24
- 230000009044 synergistic interaction Effects 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 30
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 16
- 239000003814 drug Substances 0.000 description 14
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 12
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 12
- 229960002748 norepinephrine Drugs 0.000 description 12
- 238000012360 testing method Methods 0.000 description 10
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000000725 suspension Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000009182 swimming Effects 0.000 description 7
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 239000000080 wetting agent Substances 0.000 description 5
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 4
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 4
- 230000001430 anti-depressive effect Effects 0.000 description 4
- 239000000935 antidepressant agent Substances 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 4
- 229960003147 reserpine Drugs 0.000 description 4
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000001242 postsynaptic effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 2
- 241000581650 Ivesia Species 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000005842 biochemical reaction Methods 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229960002102 imipramine hydrochloride Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000002898 effect on depression Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013210 evaluation model Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000008621 organismal health Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The application discloses a composition and application thereof. The composition comprises the following components: 5-16 parts of S-adenosylmethionine; 5-16 parts of gamma-aminobutyric acid; 5-25 parts of alpha-lactalbumin. The components of the composition are reasonably selected, have a synergistic interaction effect among the components, are scientific in proportion among the components, are compatible for use, and have a remarkable effect of treating and/or preventing depression.
Description
Technical Field
The application relates to a composition and application thereof, belonging to the technical field of health-care food.
Background
Depression is a common affective disorder, characterized primarily by a marked and persistent depression, which is manifested primarily by: the symptoms of low mood, delayed thought response, hypovolemia, anxiety, anorexia, insomnia, hypodynamia and other physical discomfort symptoms, and even extreme behaviors such as suicide. With the increasing social competition in recent years, the pace of life is increasing, and many emergency factors are increasing, so that the depression is in a high-rise situation year by year. Depression is currently ranked fourth in the world's disabling disease and has been second only to heart disease by the year 2020. In china alone, over 2600 million people suffer from depression, which brings the total economic burden to china up to 622 billion yuan.
The pathogenesis of depression is not clear so far, and the most studied monoamine neurotransmitters and their receptor hypothesis, inflammatory response hypothesis, hypothalamus-pituitary-adrenal (HPA axis) dysfunction hypothesis, neurotrophic factor hypothesis, and multifactorial combined action hypothesis are the main drugs for treating depression: tricyclic antidepressants, monoamine oxidase inhibitors and reversible selective monoamine oxidase inhibitors, 5-hydroxytryptamine (5-HT) and Norepinephrine (NE) reuptake inhibitors, NE and Dopamine (DA) reuptake inhibitors, and the like. Although these drugs can improve the depressed state to various degrees, the side effects of these drugs are large, mainly apathy, fatigue, sleep disorders, cognitive dysfunction, sexual dysfunction, stroke, and the like.
Therefore, it is imperative to use ingredients without any toxic side effects and products for treating and preventing depression with significant effects.
Disclosure of Invention
According to one aspect of the application, the composition is provided, the components of the composition are reasonably selected, the components have a synergistic interaction effect, the mixture ratio of the components is scientific, and the composition is compatible with the components and has a remarkable effect of treating and/or preventing depression.
A composition comprising the following components:
5-16 parts of S-adenosylmethionine;
5-16 parts of gamma-aminobutyric acid;
5-25 parts of alpha-lactalbumin.
S-adenosylmethionine is an important physiological active substance, and is involved in more than 40 biochemical reactions in organisms, such as gene expression, cell membrane flow to polypeptide synthesis and the like, and SAMe is involved in more important biochemical reactions in such a complex way, so that the S-adenosylmethionine has wide and various therapeutic effects and has good curative effects on depression, arthritis, liver dysfunction and the like. SAMe is the most important methyl donor in the body, methyl is provided through methionine circulation to participate in synthesis and metabolism of various important physiological active substances in the body, such as 5-hydroxytryptamine, acetylcholine, epinephrine, creatine, carnitine, dopamine and the like, and normal emotional activity is maintained; methylation of phospholipids helps to enhance receptor function, increase receptor density, and improve receptor coupling. Therefore, SAMe content and dysfunction must affect synthesis or methylation of the mediators involved in the 1-carbon metabolic pathway to cause neuropsychiatric disorders. For example, in 1966, it was suggested that "pathological methyl transfer" is a schizophrenia pathogenesis, and when monoamine transmitter anabolism is affected, neurological disorders such as depression and anxiety are inevitably caused. And SAMe is a natural substance existing in human bodies, and has no side effect.
Gamma-aminobutyric acid (GABA), also known as aminobutyric acid, is a non-protein natural amino acid, is widely distributed, and has GABA presence in animals, plants, and microorganisms. GABA is a main inhibitory neurotransmitter in the central nervous system of mammals, mediates over 40% of inhibitory nerve conduction, has a postsynaptic inhibition effect, can enable postsynaptic neurons to be in a protective inhibition state through mechanisms of postsynaptic membrane super-activation, ion influx reduction, cell metabolism reduction, oxygen consumption reduction and the like, and can reduce release of glutamic acid through presynaptic inhibition, so that death of neurons in a perfusion region is reduced, and the vitality of the neurons is improved.
Alpha-lactalbumin, a tightly structured calcium-binding globulin, is one of whey proteins, and is mainly present in breast milk. The alpha-lactalbumin is rich in various amino acids necessary for human bodies, particularly has high relative content of tryptophan, lysine and cysteine, wherein the tryptophan participates in the synthesis of regulatory protein and has the function of promoting the differentiation of bone marrow T lymphocyte precursors into mature T lymphocytes; lysine not only participates in the synthesis of body protein, but also is a precursor substance of carnitine synthesis, and participates in the beta-oxidation process of fat in vivo; cysteine is a component of glutathione and has anti-inflammatory effect.
The innovation of the application is as follows:
1. the components are reasonably selected, and particularly, the addition of S-adenosylmethionine, gamma-aminobutyric acid and alpha-lactalbumin obviously improves the treatment effect of the traditional Chinese medicine composition on depression;
2. the invention has scientific mixture ratio among the components, and particularly controls the proportion of S-adenosylmethionine, gamma-aminobutyric acid and alpha-lactalbumin to be 1: 1: 1-2: 2: 5, the efficacy of the product can be greatly improved;
3. the compatibility of medicines reduces the cost of single raw material and obviously increases the effect.
Optionally, the composition comprises the following components:
5-10 parts by weight of S-adenosylmethionine;
5-10 parts of gamma-aminobutyric acid;
5-25 parts of alpha-lactalbumin.
Optionally, the composition comprises the following components:
5-12 parts by weight of S-adenosylmethionine;
5-12 parts of gamma-aminobutyric acid;
5-15 parts of alpha-lactalbumin.
Optionally, the composition comprises the following components:
5-8 parts of S-adenosylmethionine;
5-10 parts of gamma-aminobutyric acid;
5-12 parts of alpha-lactalbumin.
Optionally, the composition comprises the following components:
8-16 parts of S-adenosylmethionine;
5-10 parts of gamma-aminobutyric acid;
12-20 parts of alpha-lactalbumin.
Optionally, the composition comprises the following components:
10-16 parts of S-adenosylmethionine;
8-10 parts of gamma-aminobutyric acid;
15-20 parts of alpha-lactalbumin.
Optionally, the composition consists of:
5-16 parts of S-adenosylmethionine;
5-16 parts of gamma-aminobutyric acid;
5-25 parts of alpha-lactalbumin.
Optionally, the composition consists of:
5-10 parts by weight of S-adenosylmethionine;
5-10 parts of gamma-aminobutyric acid;
5-25 parts of alpha-lactalbumin.
Optionally, the composition consists of:
5-12 parts by weight of S-adenosylmethionine;
5-12 parts of gamma-aminobutyric acid;
5-15 parts of alpha-lactalbumin.
Optionally, the composition consists of:
5-8 parts of S-adenosylmethionine;
5-10 parts of gamma-aminobutyric acid;
5-12 parts of alpha-lactalbumin.
Optionally, the composition consists of:
8-16 parts of S-adenosylmethionine;
5-10 parts of gamma-aminobutyric acid;
12-20 parts of alpha-lactalbumin.
Optionally, the composition consists of:
10-16 parts of S-adenosylmethionine;
8-10 parts of gamma-aminobutyric acid;
15-20 parts of alpha-lactalbumin.
According to one aspect of the application, the use of the composition of any one of the above in the preparation of a product for the treatment and/or prevention of depression is provided.
Optionally, the depression is liver disease-induced depression or postpartum depression.
Optionally, the product for treating and/or preventing depression is a health food or a pharmaceutical preparation.
According to one aspect of the present application, there is provided a health food comprising the composition of any one of the above and an adjuvant.
According to one aspect of the present application, there is provided a pharmaceutical formulation comprising the composition of any one of the above and an adjuvant.
Optionally, the health food or the pharmaceutical preparation comprises the following components:
15-51 parts by weight of the composition;
20-60 parts of a flavoring agent;
1-20 parts by weight of a binder;
0.1-1 part by weight of a flow aid.
Optionally, the flavoring agent is selected from at least one of isomalt, erythritol, sorbitol, citric acid, malic acid, stevioside, food essence and fruit and vegetable powder;
the filler is at least one selected from microcrystalline cellulose and lactose;
the glidant is selected from at least one of magnesium stearate and silicon dioxide.
According to one aspect of the present application, there is provided a method for preparing the health food or the pharmaceutical preparation according to any one of the above, the method comprising the steps of:
mixing the composition with adjuvants to obtain the health food or the pharmaceutical preparation.
As an embodiment, the present application provides a composition comprising the following components:
5-16 parts of S-adenosylmethionine;
5-16 parts of gamma-aminobutyric acid;
5-20 parts of alpha-lactalbumin.
Optionally, the composition comprises the following components:
8 parts by weight of S-adenosylmethionine
10 parts by weight of gamma-aminobutyric acid
12 parts by weight of alpha-lactalbumin
The composition provided by the application is reasonable in compatibility and synergistic, and the health food for treating depression provided by the invention has obvious effects on depression, depression caused by liver diseases, postpartum depression and the like.
The composition provided by the application has obvious effect of treating depression: it can be used for preventing and treating emotion, anxiety, insomnia, asthenia, and pain.
The composition provided by the application has the effect of treating depression, is beneficial to the health of organisms, is suitable for healthy people, endangered depressed people and depression people, is matched with S-adenosylmethionine, gamma-aminobutyric acid and alpha-lactalbumin in raw materials, is reasonably compatible in the whole formula, is mild in medicine property, and is suitable for being used by more people for a long time.
The beneficial effects that this application can produce include:
(1) the composition provided by the application has the advantages that the component selection is reasonable, the components have a synergistic interaction effect, the proportion among the components is scientific, the components are compatible for use, and the effect is remarkably improved.
(2) The composition provided by the application is matched with S-adenosylmethionine, gamma-aminobutyric acid and alpha-lactalbumin in raw materials, is reasonably compatible in the whole formula, is mild in drug property, and is suitable for long-term use by more crowds.
(3) The composition and the health food provided by the application have good application prospects in being used as products for treating and/or preventing depression.
Detailed Description
The present application will be described in detail with reference to examples, but the present application is not limited to these examples.
The raw materials in the examples of the present application were all purchased commercially, unless otherwise specified.
Examples 1 to 5,Comparative examples 1 to 5A Single component or composition
The formulations of the individual components or compositions of examples 1 to 5 and comparative examples 1 to 5 are shown in Table 1.
TABLE 1 formulation of the individual Components or compositions of examples 1-5 and comparative examples 1-5
Preparation of the composition
The powder in the embodiment 1-5 and the powder in the comparative example 1-5 are weighed according to the weight parts and uniformly mixed to obtain the corresponding single component or composition.
The preparation method of the health food or the medicine comprises the following steps:
respectively adding 54 parts by weight of sorbitol, 15 parts by weight of microcrystalline cellulose and 1 part by weight of magnesium stearate into corresponding compositions, independently granulating the sorbitol according to the formula, wherein the wetting agent is 95% edible alcohol, the amount of the wetting agent is 10 wt% of the sorbitol, adding the sorbitol into a high-efficiency wet granulator, spraying the wetting agent, starting the stirring rotating speed at 80r/min, the shearing rotating speed at 1500r/min, taking the wetting agent out of the granulator after the wetting agent is added, carrying out 20-mesh wet granulation, adding the prepared wet granules into a fluidized drying machine for drying, setting the air inlet temperature to be less than 50 ℃, and obtaining dry granules when the moisture content of the materials is less than 3%; premixing S-adenosylmethionine, gamma-aminobutyric acid, alpha-lactalbumin and half of the dry granules, adding into a total mixing tank after uniformly premixing, simultaneously adding microcrystalline cellulose and the other half of the dry granules for mixing for 30min, adding magnesium stearate, and mixing for 4min to obtain total mixed granules; and tabletting the total mixed granules to obtain a finished product.
The advantageous effects of the present application are specifically described below by way of test examples.
1. Experimental Material
(ii) animals
The Beijing-breed mice are half male and half female, and the body mass is 18-22 g. Provided by Beijing research center for laboratory animals.
② medicine and main reagent
A. Experimental drugs:
the single components or compositions (without adjuvants) prepared in examples 1-5 and comparative examples 1-5.
B. Experimental reagent:
imipramine hydrochloride (3B Scientific, usa); physiological saline (national drug group); reserpine injection (national drug group); 5-hydroxytryptamine standard (Fluka, Switzerland); norepinephrine standard (Sigma, usa).
2. Experiment method and result of forced swimming experiment, open field experiment and tail suspension experiment
120 healthy Beijing-breed mice, half of male and female, were taken, and after 1 week acclimatization, were randomly divided into 12 groups, namely, 10 mice per group, namely, a blank control group, an imipramine hydrochloride group (dose 15 mg/kg. d), and test groups (examples 1 to 5 groups and comparative examples 1 to 5 groups) (dose 15 mg/kg. d). The medicine with the corresponding dose is dissolved in distilled water every day, the medicine is administered for 1 time by intragastric administration, the administration volume is 10ml/kg, the medicine is continuously administered for 14 days, a forced swimming experiment is carried out on the 14 th day, a mouse open field experiment is carried out on the 15 th day, a mouse tail suspension experiment is carried out on the 16 th day, wherein the blank group is intragastric administered with physiological saline with the same volume.
2.1 forced swimming test of mice
The forced swimming experiment is one of behavior despair models, is a classic method of an antidepressant drug evaluation model, is also one of models commonly used for antidepressant evaluation and screening, and is widely used for basic research of psychopharmacology.
The mice were moved to a quiet test room 60min before the experiment to reduce the stress on the animals. During the experiment, the mouse is placed in a cylindrical glass container with a water depth of 10cm, a diameter of 14cm and a water temperature of 23 +/-2 ℃, the upper opening is opened, the time lasts for 6min, the whole process is recorded by a high-definition digital camera, and the total time of the mouse moving within 4min is counted by using a timer in a double-blind mode. Immobility time is defined as the time the mouse stopped struggling in the water, floated on the water surface, and moved slightly to keep the head floating on the water surface.
The results are shown in Table 2.
TABLE 2 forced swimming test results of mice
| Group of | The total time/s of mouse immobility was counted within 4min |
| Blank control group | 128.66±3.15 |
| Imipramine hydrochloride group | 90.34±1.08* |
| Example 1 | 62.77±3.03* |
| Example 2 | 38.46±2.36* |
| Example 3 | 45.89±3.01* |
| Example 4 | 54.13±2.24* |
| Example 5 | 59.64±1.78* |
| Comparative example 1 | 79.35±2.02* |
| Comparative example 2 | 70.29±1.07* |
| Comparative example 3 | 73.11±1.11* |
| Comparative example 4 | 76.32±0.58* |
| Comparative example 5 | 83.97±2.27* |
Note: p < 0.05 compared to the blank control group.
As can be seen from the data, compared with a blank control group, the immobile time of the swimming of the mice can be obviously shortened by the example group and the comparative group, wherein the shortened time of the example group is longer than that of the comparative group, and is simultaneously longer than that of the positive control group, which shows that the example group has a remarkable improvement effect on the shortening of the immobile time of the mice in a swimming despair model, and the composition has a certain antidepressant effect in a behavior despair model and generates a synergistic effect among the components.
2.2 mice open field experiment
The mice were moved to the open field experimental test room 60min before the experiment and adapted to the environment in advance. During the experiment, the mouse is taken out of the cage and placed in the center of an open field experimental device (500mm multiplied by 415mm) in an ethological test station, a shading cover curtain is rapidly pulled, and the central area is a bright room area. And (3) recording the serial number, date and state of the mouse in the operation software, then opening a recording system, recording the activity condition of the mouse within 10min through a camera above the starting equipment and a monitor connected with the camera, and recording the sum of the residence time of the central area of the mouse.
The results are shown in Table 3.
Table 3 mouse open field experimental results
| Group of | Residence time/s in the central zone |
| Blank control group | 105.67±2.05 |
| Imipramine hydrochloride group | 206.34±1.77* |
| Example 1 | 400.88±2.63* |
| Example 2 | 456.06±2.42* |
| Example 3 | 439.19±3.09* |
| Example 4 | 421.35±2.87* |
| Example 5 | 408.52±3.11* |
| Comparative example 1 | 234.01±2.55* |
| Comparative example 2 | 264.25±3.63* |
| Comparative example 3 | 251.54±2.99* |
| Comparative example 4 | 247.66±2.81* |
| Comparative example 5 | 222.49±3.27* |
Note: p < 0.05 compared to the blank control group.
Compared with a blank control group, the residence time of the example group, the comparative group and the positive control group in the central area is prolonged, and the data show that the prolonged time of the example group is longer than that of the positive control group, so that the pharmaceutical composition can prolong the residence time of the mouse in the bright room, the effect is obviously better than that of the comparative sample administration group, and the composition has a synergistic effect among the components and can obviously improve the anti-depression effect.
2.3 Tail suspension experiment
Mice were moved to the test room 60min prior to the experiment. The tail-hanging experimental frame is about 1m long, and is horizontally placed and fixed at a position which is about 30cm away from the table top. During the experiment, the tail of the mouse is fixed by an adhesive tape and hung on the tail hanging device, the head of the mouse is 8cm away from the desktop, the experiment lasts for 6min, the mouse is recorded by a high-definition digital camera, and the total motionless time of the mouse in 4min is counted by using a timer in a double-blind mode.
The results are shown in Table 4.
TABLE 4 mouse Tail suspension experiment
| Group of | Suspension tail motionless time/s |
| Blank control group | 96.63±3.99 |
| Imipramine hydrochloride group | 80.15±0.76* |
| Example 1 | 55.98±1.07* |
| Example 2 | 40.33±1.13* |
| Example 3 | 43.04±1.22* |
| Example 4 | 47.61±1.34* |
| Example 5 | 50.27±1.55* |
| Comparative example 1 | 76.02±2.01* |
| Comparative example 2 | 63.19±1.95* |
| Comparative example 3 | 67.42±1.14* |
| Comparative example 4 | 71.55±1.50* |
| Comparative example 5 | 79.08±1.68* |
Note: p < 0.05 compared to the blank control group.
Compared with a blank control group, the tail suspension immobility time of the example group, the comparative example group and the positive control group can be reduced, and the data show that the tail suspension immobility time of the example group is more obvious than that of the positive control group, so that the composition can obviously reduce the tail suspension immobility time of mice through the synergistic effect of the components, and the effect is obviously better than that of the comparative example sample administration group and the positive control group, so that the composition has a remarkable effect on resisting depression.
3. Detection of 5-hydroxytryptamine and norepinephrine levels in brain tissue
The monoamine neurotransmitter hypothesis is the most studied and most profound hypothesis, and the 5-hydroxytryptamine and norepinephrine systems, which are the basis for most of the current clinical antidepressants, are still important systems for evaluating antidepressant components. When 5-hydroxytryptamine and norepinephrine in the brain are below normal, there is insufficient excitability and mood is in a state of negative depression, which over time causes depression.
Reserpine can exhaust monoamine transmitter in mouse brain, produce depression symptom, and be used as monoamine evacuator to establish depression animal model.
130 healthy Beijing-breed mice are selected, male and female are half of the healthy Beijing-breed mice, and after 1 week of adaptation to the environment, the healthy Beijing-breed mice are randomly divided into 13 groups, namely a blank control group, a imipramine hydrochloride group (the dose is 15 mg/kg. d), a model group and a test group (the dose is 15 mg/kg. d) (examples 1-5 groups and comparative examples 1-5 groups), and 10 mice are selected in each group. The model group, the imipramine hydrochloride group and the tested group are all injected subcutaneously for 6 days by 0.25mg/kg reserpine, the gastric perfusion of 10ml/kg of physiological saline is started on the 3 rd day of the model group, the gastric perfusion of the composition aqueous solution with the same volume is started on the 3 rd day of the tested group, the gastric perfusion of the imipramine hydrochloride aqueous solution with the same volume is continuously performed for 10 days, after the administration for 0.5h on the 10 th day, cervical vertebra dislocation is performed, the brain is rapidly cut off, the weight is measured, the cerebellum is removed in ice bath, a glass homogenizer for ice bath is used for preparing brain tissue homogenate, and the content of 5-hydroxytryptamine and norepinephrine is measured. The blank group was gavaged daily with an equal volume of saline, and the same model group and test group were treated 0.5h after the administration on day 10.
The results of the mouse 5-hydroxytryptamine and norepinephrine levels are shown in Table 5.
TABLE 5 mouse 5-Hydroxytryptamine and norepinephrine levels assay
Note: compared with the blank control group, the composition of the composition,#p < 0.05, p < 0.05 compared to model group.
Compared with a blank control group, the water average of 5-hydroxytryptamine and norepinephrine in the brain tissue of the mouse in the model group is obviously reduced, which indicates that the molding is successful. Compared with the model group, the administration group of the embodiment can obviously improve the levels of 5-hydroxytryptamine and norepinephrine of the model mouse, and the effect is obviously better than that of the comparative example. The administration group of the illustrated example has a significant improvement effect on depression symptoms caused by reserpine.
The above experimental results show that the antidepressant effect of the composition is obviously better than that of the administration group of the comparative sample and better than that of the imipramine hydrochloride group.
Although the present application has been described with reference to a few embodiments, it should be understood that various changes, substitutions and alterations can be made herein without departing from the spirit and scope of the application as defined by the appended claims.
Claims (10)
1. A composition, comprising the following components:
5-16 parts of S-adenosylmethionine;
5-16 parts of gamma-aminobutyric acid;
5-25 parts of alpha-lactalbumin.
2. The composition according to claim 1, characterized in that it comprises the following components:
5-8 parts of S-adenosylmethionine;
5-10 parts of gamma-aminobutyric acid;
5-12 parts of alpha-lactalbumin.
3. The composition according to claim 1, characterized in that it consists of:
5-16 parts of S-adenosylmethionine;
5-16 parts of gamma-aminobutyric acid;
5-25 parts of alpha-lactalbumin.
4. Use of a composition according to any one of claims 1 to 3 in the manufacture of a product for the treatment and/or prevention of depression.
5. The use according to claim 4, wherein the depression is liver disease-induced depression or postpartum depression.
6. The use according to claim 5, wherein the product for the treatment and/or prevention of depression is a health food or a pharmaceutical preparation.
7. A health food comprising the composition of any one of claims 1 to 3 and an adjuvant.
8. A pharmaceutical formulation comprising the composition of any one of claims 1 to 3 and an adjuvant.
9. The nutraceutical or pharmaceutical preparation according to claim 7 or 8, wherein the nutraceutical or pharmaceutical preparation comprises the following components:
15-51 parts by weight of the composition;
20-60 parts of a flavoring agent;
1-20 parts by weight of a binder;
0.1-1 part by weight of a flow aid;
preferably, the flavoring agent is selected from at least one of isomalt, erythritol, sorbitol, citric acid, malic acid, stevioside, edible essence and fruit and vegetable powder;
the filler is at least one selected from microcrystalline cellulose and lactose;
the glidant is selected from at least one of magnesium stearate and silicon dioxide.
10. A process for preparing a nutraceutical or pharmaceutical formulation according to any of claims 7 to 9, comprising the steps of:
mixing the composition and the auxiliary materials to obtain the health-care food or the pharmaceutical preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110585553.8A CN113397171A (en) | 2021-05-27 | 2021-05-27 | Composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110585553.8A CN113397171A (en) | 2021-05-27 | 2021-05-27 | Composition and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113397171A true CN113397171A (en) | 2021-09-17 |
Family
ID=77674770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110585553.8A Pending CN113397171A (en) | 2021-05-27 | 2021-05-27 | Composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113397171A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101677543A (en) * | 2007-01-31 | 2010-03-24 | 甲基化物科学国际有限公司 | The time-delay release pharmaceutical formulations of S-adenosylmethionine |
| CN109620863A (en) * | 2018-12-19 | 2019-04-16 | 泓博元生命科技（深圳）有限公司 | A kind of composition and the preparation method and application thereof for alleviating depression |
| CN110959824A (en) * | 2018-09-30 | 2020-04-07 | 石家庄以岭药业股份有限公司 | Tranquilizing composition and preparation method thereof |
-
2021
- 2021-05-27 CN CN202110585553.8A patent/CN113397171A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101677543A (en) * | 2007-01-31 | 2010-03-24 | 甲基化物科学国际有限公司 | The time-delay release pharmaceutical formulations of S-adenosylmethionine |
| CN110959824A (en) * | 2018-09-30 | 2020-04-07 | 石家庄以岭药业股份有限公司 | Tranquilizing composition and preparation method thereof |
| CN109620863A (en) * | 2018-12-19 | 2019-04-16 | 泓博元生命科技（深圳）有限公司 | A kind of composition and the preparation method and application thereof for alleviating depression |
Non-Patent Citations (1)
| Title |
|---|
| 宁亚维，等: "γ-氨基丁酸的制备方法及其功能食品研究进展", 《食品与发酵工业》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2078019C (en) | Substance or composition and uses thereof | |
| JP2023027149A (en) | Formulations for extending lifespan and healthspan | |
| US20070298081A1 (en) | Physiologically active agents containing vicinal dithioglycols and use thereof in various branches of economy | |
| EP3416501A1 (en) | Nutritional support for animals via administration of an algal derived supplement | |
| TW201417718A (en) | Methods for improving health in animals | |
| CN103493983B (en) | Feed additive for improving fur quality of fur-bearing animal and manufacturing method thereof | |
| N’nanle et al. | Effect of in ovo inoculation of Moringa oleifera leaves extract on hatchability and chicken growth performance | |
| JP2002125662A (en) | Non-deactivated enzyme-reinforced composition | |
| RU2538721C1 (en) | Method of treatment of subclinical mastitis in lactating cows | |
| CN113397171A (en) | Composition and application thereof | |
| RU2283114C1 (en) | Composition with hepatoprotective and metabolism normalizing activity | |
| KR102439576B1 (en) | Composition of Nutrient Delivery System for Improving Brain Function | |
| RU2702658C1 (en) | Injection agent for treating and preventing liver diseases in animals | |
| RU2549496C1 (en) | Homeopathic medicinal product having stress-protective and growth-stimulating effect, regulating metabolism in young farm animals and poultry | |
| WO2021212700A1 (en) | Pharmaceutical composition for improving motion sickness of pets, preparation method therefor and use method thereof | |
| CN114514956A (en) | Gel hollow candy for assisting in feeding pet medicaments, and preparation method and application thereof | |
| RU2455978C1 (en) | Rectal suppositories for treatment of hemorrhoids, proctitis and other proctological diseases | |
| RU2341276C1 (en) | Method of gastrointestinal disturbance prevention in newborn calfs | |
| KR101041044B1 (en) | A composition for reducing sleep induction time and prolonging sleeping time, and a method for preparing the same | |
| CN101732695B (en) | Compound of brain protein hydrolyzate and maleic acid and method for preparing same | |
| JP2007230954A (en) | Sleep inducer and stress insomnia-improving agent | |
| CN109619287B (en) | Application of purine | |
| CN115025124B (en) | Hematopoietic anti-aging active component extracted from chick embryo tissue and application thereof | |
| Abd El‐Aziz et al. | Impact of bee venom supplement on productive performance, health status and economics of weaned male rabbits: Considering breed and dosage factors | |
| Kurbonov et al. | Use Of Pomegranate Marc In Composition Of Compound Feed For The Prevention Of Diarrhea Of Farming Poultry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210917 |
|
| RJ01 | Rejection of invention patent application after publication |